Inventor · disambiguated record
Daozhong Zou
Also filed as: ZOU DAOZHONG
20 granted patents·2 pending applications·115 citations·filing 2006–2023
93Inventor score
Top patents by PatentIndex Score
22 records- 0197US9365524B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2015·Granted Jun 14, 2016·22 cites·36 claims
- 0296US9814713B2Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their useSIGNAL PHARM LLC·Filed 2016·Granted Nov 14, 2017·14 cites·21 claims
- 0392US10882867B2Forms and compositions of a MK2 inhibitorCELGENE CAR LLC·Filed 2018·Granted Jan 5, 2021·8 cites·23 claims
- 0492US7655657B2Fused bicycloheterocycle substituted quinuclidine derivativesABBOTT LAB·Filed 2007·Granted Feb 2, 2010·44 cites·5 claims
- 0591US9796685B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2015·Granted Oct 24, 2017·14 cites·7 claims
- 0690US11434200B2Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereofNOVARTIS AG·Filed 2020·Granted Sep 6, 2022·2 cites·24 claims
- 0784US10131639B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2017·Granted Nov 20, 2018·4 cites·18 claims
- 0883US11629153B2Forms and compositions of a MK2 inhibitorCELGENE CAR LLC·Filed 2020·Granted Apr 18, 2023·1 cites·33 claims
- 0982US11629124B2Solid forms comprising an oxime ether compound, compositions and methods of use thereofNOVARTIS AG·Filed 2020·Granted Apr 18, 2023·1 cites·10 claims
- 1081US11013723B1Solid forms of a thiazolidinone compound, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted May 25, 2021·2 cites·30 claims
- 1174US12049446B2Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereofNOVARTIS AG·Filed 2022·Granted Jul 30, 2024·0 cites·13 claims
- 1274US10590089B2Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamideSIGNAL PHARM LLC·Filed 2018·Granted Mar 17, 2020·1 cites·48 claims
- 1370US10005760B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2015·Granted Jun 26, 2018·1 cites·21 claims
- 1470US2023219887A1Solid forms comprising an oxime ether compound, compositions and methods of use thereofNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1560US11958805B2Solid forms comprising an oxime ether compound, compositions and methods of use thereofNOVARTIS AG·Filed 2020·Granted Apr 16, 2024·0 cites·38 claims
- 1659US10202364B2Forms and compositions of an ERK inhibitorCELGENE CAR LLC·Filed 2018·Granted Feb 12, 2019·0 cites·16 claims
- 1757US11014897B1Solid forms comprising a thiazolidinone compound, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted May 25, 2021·0 cites·20 claims
- 1851US11186556B1Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereofCELGENE CORP·Filed 2019·Granted Nov 30, 2021·0 cites·24 claims
- 1946US2018258064A1Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and usesCELGENE CORP·Filed 2018·Application pending·0 cites
- 2045USD1055400SPet carrierZOU DAOZHONG·Filed 2022·Granted Dec 24, 2024·1 cites·1 claims
- 2145US8124129B2Crystalline form of the compound A-348441CINK RUSSELL DREW·Filed 2006·Granted Feb 28, 2012·0 cites·18 claims
- 2232US10064863B2Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dioneCELGENE CORP·Filed 2016·Granted Sep 4, 2018·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Daozhong Zou files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →